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Background: Involuntary movements, neuropsychiatric symptoms, and cognitive impairment are all part of the
symptom triad in Huntington’s disease (HD). Despite the fact that neuropsychiatric symptoms and cognitive decline
may be early manifestations of HD, the clinical diagnosis is conventionally based on the presence of involuntary
movements and a positive genetic test for the HD CAG repeat expansion. After investigating the frequencies of the
triad manifestations in a large outpatient clinical cohort of HD gene-expansion carriers, we propose a new clinical
classification.
Methods: In this cross-sectional study, 107 gene-expansion carriers from a Danish outpatient clinic were recruited. All
participants underwent neurological examination, psychiatric evaluation and neuropsychological testing. Participants
were categorised according to motor symptoms, neuropsychiatric symptoms, the use of psychotropic medication, and
cognitive impairment.
Results: Among the motor manifest HD gene-expansion carriers, 51.8% presented with the full symptom triad,
25.0% were defined as cognitively impaired in addition to motor symptoms, and 14.3% had neuropsychiatric
symptoms along with motor symptoms. Only 8.9% had isolated motor symptoms. Among gene-expansion carriers
without motor symptoms, 39.2% had neuropsychiatric symptoms, were cognitively impaired, or had a combination of
the two.
Conclusion: This is the first study to report the frequencies of both motor symptoms, cognitive impairment, and
neuropsychiatric symptoms in HD gene-expansion carriers in a national outpatient HD clinical cohort. We found
that almost 40% of the gene-expansion carriers without motor symptoms had either neuropsychiatric symptoms,
cognitive impairment or both, emphasising that these patients are not premanifest in psychiatric and cognitive
terms, suggesting that the current clinical classification is neither necessarily suitable nor helpful for this patient
group. Some premanifest gene-expansion carriers may have psychiatric and/or cognitive symptoms caused by
reactive stress or other pathology than HD. Acknowledging this fact we, however, suggest classifying all HD
gene-expansion carriers into three clinical categories: premanifest, non-motor manifest, and motor manifest.
Keywords: Huntington’s disease, Clinical classification, Neuropsychiatry, Cognitive impairment, Premanifest* Correspondence: jnielsen@sund.ku.dk
†Equal contributors
1Neurogenetics Clinic, Danish Dementia Research Centre, Department of
Neurology, Rigshospitalet, University of Copenhagen, Section 6922,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark
2Department of Cellular and Molecular Medicine, Section of Neurogenetics,
University of Copenhagen, Copenhagen, Denmark
Full list of author information is available at the end of the article
© 2014 Vinther-Jensen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Vinther-Jensen et al. Orphanet Journal of Rare Diseases 2014, 9:114 Page 2 of 9
http://www.ojrd.com/content/9/1/114Introduction
Huntington’s disease (HD) is an autosomal dominant
neurodegenerative disorder presenting with progressive
motor, cognitive, and neuropsychiatric symptoms [1].
The disease is caused by an expanded CAG repeat in the
Huntingtin gene [2].
Since the first descriptions of HD it has been known
that both “insanity” and “deterioration of the mind” in
combination with chorea are part of the disease
spectrum [3]. Currently, the clinical diagnosis is still
based on unequivocal motor signs. For more than a
decade, however, it has been acknowledged that in
some cases the psychiatric and/or cognitive symptoms
occur early in HD and may precede the motor symp-
toms by several years [4-6]. Moreover, for some pa-
tients, the psychiatric and cognitive symptoms tend to
have a greater impact on maintaining everyday func-
tioning and quality of life than the motor symptoms do
[7]. The inadequacy of the motor criterion for clinical
diagnosis of HD has recently been addressed by Loy
and McCusker. They demonstrated, from a series of
cases, the shortcomings of this motor-only diagnostic
approach, arguing that both cognitive and psychiatric
symptoms should be taken into account when giving a
person the clinical diagnosis of HD [8].
The psychiatric symptoms found in HD are primarily ir-
ritability, depression, anxiety, and apathy [9]. The symp-
toms are assumed to be caused by the pathophysiological
changes occurring in HD and not the awareness that a dev-
astating disease will develop [4,6,10]. The manifestations
and prevalence of psychiatric symptoms in HD gene-
expansion carriers without motor symptoms have been
questioned and discussed for over a decade [4,9-11]. Two
recent large multi-site longitudinal prospective studies de-
signed to identify and track markers of HD prior to the on-
set of motor symptoms (PREDICT-HD and TRACK-HD)
showed that both premanifest and manifest HD gene-
expansion carriers revealed more psychiatric symptoms
than healthy controls [12,13].
Cognition has also been studied intensively in HD in
the last ten years. Cognitive impairments are predomin-
antly found in attention, executive function, and in psy-
chomotor speed [14,15]. In the PREDICT-HD study,
“prodromal” HD gene-expansion carrier performance on
cognitive test was dependent on proximity to diagnosis;
individuals with < 9 years to diagnosis performed signifi-
cantly worse than controls on 40 out of 51 tests [16]. In
another paper form the PREDICT-HD study, nearly 40%
of so-called “prediagnosed” HD gene-expansion carriers
had a level of cognitive impairment that corresponded
to the definition of mild cognitive impairment (MCI)
[17]. In the TRACK-HD study, premanifest HD muta-
tion carriers close to a clinical HD diagnosis showed a
decline in cognition during a three-year period [18].In previous studies on cognitive deficits and psychiatric
symptoms, focus has been on the identification of sensi-
tive measures of symptoms, and the large majority of
studies have used comparisons at a group level to assess
differences with regard to these symptoms [13,16,19,20].
Other studies have focused on finding tests, scales or
symptoms that could predict disease progression and/or
phenoconversion [16,18]. The frequency of cognitive defi-
cits and psychiatric symptoms per se has, to our know-
ledge, never been investigated in a single large national
cohort of manifest and premanifest HD gene-expansion
carriers. Consequently, the objective of the present study
is to investigate the frequency of motor symptoms, cogni-
tive impairment, and psychiatric symptoms in a large
group of HD gene-expansion carriers from a Danish HD
outpatient clinic. Based on our results we propose a new
clinical classification.
Methods
Subjects
Participants were recruited from January 2012 to March
2013 from the Neurogenetics Clinic, Danish Dementia Re-
search Centre, Rigshospitalet, Copenhagen, Denmark. At
the time of recruitment this clinic was the only specialised
HD clinic in Denmark that general practitioners, clinical
genetics departments, neurological departments or any
other hospital department in the country referred HD
gene-expansion carriers to, irrespective of being symp-
tomatic or not. All individuals with a CAG repeat ≥39
and a Unified Huntington’s Disease Rating Scale-99,
(UHDRS-motor) [21] total motor score ≤55, a Mini
Mental State Examination (MMSE) score ≥24, and a
Montreal Cognitive Assessment (MoCA) [22] score ≥19
were eligible for inclusion. Exclusion criteria were on-
going alcohol or drug abuse, and having a native lan-
guage other than Danish. All individuals had been
through a genetic counselling process and informed of
their genetic status prior to participating in the study.
The study was approved by the Ethics Committee of
the Capital Region of Denmark (H2-2011-085), and
written informed consent was obtained from each par-
ticipant before enrolment.
All participants had a minimum of two planned visits.
At the first visit the following examinations were per-
formed: physical and neurological examination and
neuropsychiatric evaluation. Neuropsychological testing
was performed at the second visit. The two visits were
performed in random order and the evaluations were
performed blinded to one another. The same physician
and neuropsychologist performed all examinations. A
group of forty healthy HD gene-expansion negative indi-
viduals who were offspring of a HD gene-expansion car-
rier (and had been genetically tested with a CAG repeat
length of less than 30) were included as controls to
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and cognitive assessments.
Clinical evaluation
UHDRS-motor was applied to evaluate motor signs. Par-
ticipants with a UHDRS-motor score of >5 were classi-
fied as motor manifest HD gene-expansion carriers. If
the score was ≤5, indicating no substantial motor signs,
they were classified as premanifest HD gene-expansion
carriers. Furthermore, the subjects were assessed with
UHDRS Total Functional Capacity (TFC) and UHDRS
Function scales. Previous medical and psychiatric history
was investigated and current medication noted. MoCA
and MMSE were applied as cognitive screening instru-
ments to exclude patients with cognitive impairment
to a degree where neuropsychological testing would be
unrewarding.
Neuropsychiatric assessment and classification
To assess neuropsychiatric symptoms, the Symptom
Checklist-90-Revised (SCL-90-R) [23] and the Hamilton
Rating Scale for Depression-17 (HAM-17) were adminis-
tered [24]. The SCL-90-R is a 90-item self-report symp-
tom inventory designed to reflect the status of current
psychological symptoms [23]. Each of the 90 items is rated
on a five-point Likert scale of distress, ranging from “not
at all” to “extremely”. Subsequently the questions and
answers are divided into nine primary symptom dimen-
sions: somatization (SOM), obsessive-compulsive (O-C),
interpersonal sensitivity (I-S), depression (DEP), anxiety
(ANX), hostility (HOS), phobic anxiety (PHOB), paranoid
ideation (PAR), and psychoticism (PSY). The SCL-90-R
also yields three global indices of distress: Global Severity
Index (GSI), Positive Symptoms Distress Index (PSDI),
and Positive Symptoms Total (PST) [23]. Raw scores can
be converted to T-scores normalised to a Danish sample
of non-psychiatric individuals sorted by gender [25].
Higher T-scores indicate more psychiatric distress.
The investigator administered the HAM-17 in a semi-
structured interview covering the 17 symptom areas.
Participants were allocated to the neuropsychiatric
group based on at least one of the following criteria:
1. Usage of psychotropic medication
2. A SCL-90-R GSI T-score ≥63 or a T-score ≥63 in
more than two of the nine primary symptom
dimensions. The SCL-90-R cut-offs are based on
SCL-90-R guide [23,26]
3. A HAM-17 score ≥13 (moderate to severe
depression) [27]
Neuropsychological testing and classification
Pre-morbid intellectual level was assessed by the Wechsler
Adult Intelligence Scale (WAIS) Vocabulary subtest andthe Danish Adult Reading Test (DART), a Danish equiva-
lent of the National Adult Reading Test [28]. Memory was
assessed with the Selective Reminding Test, both immedi-
ate recall (errors were recorded) and delayed recall (reten-
tion interval 10 min) [29] and the Rey Complex Figure
Test (recall 3 min) [30]. Psychomotor speed/Attention was
assessed by Trail Making Test A & B [31] (only comple-
tion time used for analyses) and Symbol Digit Modalities
Test [32]. Executive functions were assessed with the
Stroop test (100 items) [33] and verbal fluency tests. For
the Stroop test, only performance on the incongruent ver-
sion was used for analyses (only completion time was
used). We applied three verbal fluency tests: category flu-
ency (animals, 1 min) and lexical fluency (s-words and a-
words, 1 min); these measures were analysed separately.
Visuospatial functions were assessed using a Rey Complex
Figure [30], Ravens Progressive Matrices (set 1) [34], and a
modified version of the Block Design Test [35].
The normative data for the neuropsychological tests
used in this study were derived from the test results
from 80 age-matched healthy subjects, retrieved from a
database at the Department of Neurology, Rigshospitalet,
University of Copenhagen. For each test, expected scores
were generated from factors based on regression ana-
lyses including age, years of education and general verbal
intellectual level (as assed by the Vocabulary subtest
from WAIS and DART). To assess if observed scores
differed from expected scores and could be categorised
as impaired, the variation in residual values from the re-
gression analyses was used. Difference scores between
observed and expected scores were used to evaluate im-
pairment [36]. Scores above the tenth percentile of the
normal variation in the regression analyses were cate-
gorised as unimpaired, whereas difference scores in the
lowest 10% of the normal variation were categorised as
impaired.
The following criteria for classifying a patient as cogni-
tively impaired were applied: a) if four (or more) test
performances were categorised as impaired; b) if all test
performances in a domain (except psychomotor speed/
attention) were impaired; c) if performances on all tests
in the psychomotor speed/attention domain, and if at
least one other test, were below the cut-off.
Data analysis
Participants were classified into four groups based on
the presence of cognitive impairment and neuropsychi-
atric symptoms. The relative frequency of the groups
was estimated for manifest and pre-manifest subjects.
Using logistic regression analysis, we then explored
whether demographic and clinical variables predicted
the symptom dimensions. In the manifest group, we
modelled the risk of having both cognitive impairment
and neuropsychiatric symptoms as a function of relevant
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disease duration. For the premanifest group we modelled
the risk of having either cognitive impairment, neuro-
psychiatric symptoms, or both as a function of the co-
variates mentioned above and the disease burden score
((CAGn – 35.5)*Age) [37]. The covariates were initially
included one at a time, and then a model including all
covariates was developed. Effects are presented as odds
ratios (OR).
In addition, we compared the neuropsychological and
neuropsychiatric test scores between manifest and pre-
manifest subjects. These outcomes approximately followed
normal distributions, and the comparison was therefore
based on an independent sample t-test. A p-value of less
than 0.05 was considered significant.
Results
One hundred and thirty-four gene-expansion carriers
were asked to participate; 12 were excluded due to either
low scores on MoCA or MMSE, and/or high scores on
UHDRS motor. Fifteen did not meet on arranged trail
dates or declined to participate in the study.
One hundred and seven participants fulfilled the inclu-
sion criteria and completed the study programme, 51
were premanifest gene-expansion carriers according to
the motor criterion and the remaining 56 were motor
manifest. Table 1 contains clinical data from the two
groups. There was no significant difference in gender or
CAG repeat length in the two groups, but the motor
manifest group, as expected, was significantly older and
had higher UHDRS motor and lower TFC scores than
the premanifest group. In the premanifest group the ma-
jority (>90%) completed the genetic counseling and test-
ing procedure more than one year prior to inclusion in
this study.
There were no significant differences between the two
groups on the HAM-17 rating scale or on the SOM, I-S,
ANX, HOS, PHOB, and PAR SCL-90-R symptomTable 1 Clinical characteristics of the two groups of participa
Premanifest HD gene-expansion carriers
N = 51
Gender (m/f )§ 30/21
Age at examination# (years) 36 (20–54)
CAG repeat length# 42 (39–48)
Disease burden scorea 234.0 (108.0–437.0)
UHDRS-motorb (score)# 2 (0–5)
TFCc (score)# 13 (11–13)
MMSE (score)# 29 (26–30)
MoCA (score)# 28 (25–30)
Data are presented as median (range).
p values were calculated by §Chi-square-test or #Mann–Whitney U test.
aDisease burden score = ((CAGn – 35.5)*Age);
bUHDRS-motor: Unified Huntington’s Disedimensions, but on the O-C, DEP, PSY symptom dimen-
sions and, on GSI, motor manifest gene-expansion car-
riers had significantly higher scores compared to the
premanifest gene-expansion carriers (Table 2). After
Bonferroni correction, these differences, except the O-C
dimension, became insignificant. On all neuropsycho-
logical tests motor manifest HD gene-expansion carriers
performed significantly worse as compared to premani-
fest HD gene-expansion carriers (Table 2).
The validity of the criteria for neuropsychiatric and
cognitive assessment was tested by applying them to the
group of 40 healthy gene-expansion negative individuals.
Among these, two participants (5.0%) fulfilled the cri-
teria for neuropsychiatric grouping and two participants
(5.0%) were classified as cognitively impaired; one par-
ticipant could be classified both with neuropsychiatric
symptoms and as cognitively impaired.
Neuropsychiatric classification
The diagram in Figure 1 shows the classification of the
participants into the neuropsychiatric group and non-
neuropsychiatric group. Among the premanifest gene-
expansion carriers ten participants (19.6%) were treated
with antidepressants and 51.1% of all participants taking
antidepressants had neuropsychiatric symptoms according
to the SCL-90-R. In the motor manifest group, 35 partici-
pants (61.0%) were treated with antidepressants; of these
51.4% had neuropsychiatric symptoms according to the
SCL-90-R. Among participants without psychotropic medi-
cation seven, (five premanifest (9.8%) and two motor mani-
fest (3.6%)) had neuropsychiatric symptoms according to
the SCL-90-R criteria. Participants were taking different
antidepressants (including SSRI, SNRI, and NaSSA). Two
patients had antipsychotics alone: One was classified in the
neuropsychiatric group based on the SCL-90-R score while
the other had tetrabenazine solely for involuntary move-
ments and scores below the cut-off in SCL-90-R. This pa-
tient was categorised as non-neuropsychiatric.nts
Motor manifest HD gene-expansion carriers Level of significance
N = 56 p-values
33/23 p = 0.32
50 (24–75) p < 0.001
43 (40–53) p < 0.38
21 (6–51) p < 0.001
10 (4–13) p < 0.001
28 (24–30) p < 0.001
25 (19–30) p < 0.001
ase Rating Scale-99, range (0–124); cTFC: Total Function Capacity, range (0–13).
Table 2 Neuropsychiatric symptoms and neuropsychological test performances in the premanifest and the motor
manifest gene-expansion carriers
Premanifest HD
gene-expansion carriers
Motor manifest HD
gene-expansion carriers
Level of significance
N = 51 N = 56 p-value
Neuropsychiatric scales
SCL-90-Ra
Global Severity Index 49.6 (10.1) 53.6(10.2) 0.041
Somatization 50.5 (9.7) 50.5 (9.9) 0.979
Obsessive-compulsive 49.5 (10.3) 57.25 (10.2) <0.001
Interpersonal Sensitivity 47.9 (10.5) 51.2 (12.0) 0.134
Depression 49.3 (10.5) 54.0 (9.0) 0.014
Anxiety 50.1 (10.9) 53.0 (9.46) 0.141
Anger-hostility 53.3 (11.6) 52.8 (12.7) 0.848
Phobic anxiety 50.7 (11.1) 55.1 (12.8) 0.059
Paranoid ideation 47.4 (9.7) 47.2 (9.6) 0.915
Psychoticism 47.8 (9.2) 53.4 (10.9) 0.005
Positive Symptoms Total 49.9 (10.0) 52.6 (9.1) 0.142
Positive Symptoms Distress Index 52.6 (10.3) 55.7 (10.8) 0.141
HAM-17b 4.5 (4.6) 5.8 (3.7) 0.103
Neuropsychological tests
Trail Making Test A (seconds) 22.8 (5.2) 45.3 (21.2) <0.001
Trail Making Test B (seconds) 62.2 (16.7) 131.8 (55.5) <0.001
Symbol Digit Modalities Test (number correct) 49.6 (8.1) 28.3 (9.4) <0.001
Stroop interference (seconds) 119.0 (21.0) 193.5 (77.3) <0.001
Category verbal fluency 24.1 (4.2) 16.6 (6.4) <0.001
Lexical fluency, s-words 14.5 (3.9) 10.7 (5.1) <0.001
Lexical fluency, a-words 9.4 (3.9) 5.7 (3.1) <0.001
Reys Complex Figure Test, recall 24.3 (6.3) 18.3 (6.0) <0.001
Reys Complex Figure Test, copy 35.6 (1.0) 34.0 (2.4) <0.001
Block design (number correct) 11.9 (0.4) 10.8 (1.8) <0.001
Raven’s Advanced Progressive Matrices 9.5 (1.7) 6.5 (2.6) <0.001
Selective Reminding Test, immediate recall
(number of errors)
12.49 (7.9) 28.17 (11.6) <0.001
Selective Reminding Test, delayed recall 7.57 (1.7) 6.02 (2.1) <0.001
aSymptom Checklist-90-R. Data shown as mean (SD). p values were calculated by independent sample t-tests. bHamilton Rating Scale for Depression-17.
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The large majority of motor manifest gene-expansion
carriers (N = 43, 76.8%) and a subset of the premanifest
gene-expansion carriers (N = 7, 13.7%) were classified as
cognitively impaired according to our criteria.
Clinical characterisation of the HD gene-expansion
carriers
Figure 2 shows the distribution of cognitive impairment
and neuropsychiatric symptoms in the motor manifest
group. Very few had isolated motor symptoms (8.9%),
and more than half (51.8%) had a symptom complexwith motor symptoms, neuropsychiatric symptoms, and
cognitive impairment.
Covariates were not able to predict whether motor
manifest gene-expansion carriers displayed the full triad
of symptoms or not. Male gender, younger age, longer
CAG repeat length, higher UHRDS score, and shorter
disease duration were associated with an increased risk
for having both neuropsychiatric symptoms and cognitive
impairment, but none of these effects was statistically sig-
nificant (data not shown). Effects remained insignificant
when included simultaneously in a multiple logistic re-
gression model. However, a decrease in TFC score was
Figure 1 Flowchart used for categorisation of participants into the neuropsychiatric vs. the non-neuropsychiatric groups.
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(OR=0.50, p<0.001).
In the premanifest group, 60.8% were classified without
neuropsychiatric symptoms and/or cognitive impairment
(Figure 3), and 39.2% had neuropsychiatric symptoms,
cognitive impairment or a combination of the two. Logis-
tic regression models showed that male gender, older
age, shorter CAG repeat length and higher disease bur-
den predicted an increased risk of being in the group
with cognitive impairment, neuropsychiatric symptoms,
or both. However, all effects were far from reaching statis-
tical significance. Effects remained insignificant when in-
cluded simultaneously in a multiple regression model.
Discussion
To our knowledge, this is the first study to investigate
the frequency of both psychiatric symptoms and cogni-
tive impairment in a national clinical cohort of premani-
fest to moderately affected HD gene-expansion carriers. InFigure 2 Distribution of cognitive impairment and neuropsychiatric
symptoms in the motor manifest HD gene-expansion carriers.this cross-sectional study the triad of motor symptoms,
neuropsychiatric symptoms, and cognitive impairment was
found in 51.8% of all motor manifest HD gene-expansion
carriers. Further, we showed that among the premanifest
HD gene-expansion carriers, 39.2% had neuropsychiatric
symptoms, cognitive impairment, or both.
In the motor manifest group, 76.8% of the patients ful-
filled the criteria for cognitive impairment. The results
show that cognitive deficits are found in the large major-
ity of the motor manifest patients seen in the clinic
(even in the early stages of HD). In addition, the results
imply that cognitive evaluation is very important in HD
motor manifest patients, since such deficits could have a
negative effect on the patient’s ability to, for example,
maintain a job, manage household finances, or drive a car.
In the premanifest group, 13.7% were classified as
cognitively impaired. The premanifest gene-expansion
carriers are generally considered to be healthy and
are treated as such; however, the results show thatFigure 3 Distribution of cognitive impairment and neuropsychiatric
symptoms in the premanifest HD gene-expansion carriers.
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relevant, e.g. to try to prevent financial stagnation and
social exclusion. The frequency of cognitive impairment
in HD has been investigated in a previous study, and the
frequency of MCI in “prediagnosed” HD gene-expansion
carriers was examined using standard criteria for MCI
(test performance in one of four tests below 1.5 standard
deviations on age- and education-adjusted normative
data). MCI was found in 39.8% and multiple-domain
MCI (two or more tests below 1.5 standard deviations)
in 13.9% of the “prediagnosed” HD gene-expansion car-
riers [17]. The methodology of our study compared to
the MCI study is different, and we used a more conser-
vative classification of cognitive impairment and the pre-
manifest status. Importantly, both studies show that
cognitive impairment is present in some presymptomatic
HD gene-expansion carriers. Our study further suggests
that cognitive symptoms in premanifest HD are not only
mild, but also that premanifest HD gene-expansion car-
riers may have cognitive deficits to an extent where they
may be classified as cognitively impaired.
According to our predefined criteria, 66.1% in the
motor manifest group and 29.4% in the premanifest
group were classified to the neuropsychiatric group. Pre-
vious studies have reported very different lifetime preva-
lence of psychiatric symptoms in HD gene-expansion
carriers that varies from 24.7% to 76.0% in manifest pa-
tients [9]. A recent study reported a 12-month preva-
lence of psychiatric symptoms of 24.7% in manifest and
of 27.3% in premanifest HD gene-expansion carriers [6].
The frequencies in our study are markedly higher as
compared to Van Duijn et al’s study [6]. We chose an all
or none approach in our study. If the participants had
an intake of psychotropic medication, they were classi-
fied in the neuropsychiatric group, without regard to
their current psychiatric symptoms. Psychotropic medi-
cation is prescribed by physicians who have found indi-
cation for the treatment. Moreover, we assume that the
participants taking psychotropic medication do so be-
cause they have an underlying psychiatric disorder and
the majority of these patients would probably have
affective or other psychiatric symptoms if their medica-
tion were paused. Therefore, not classifying patients on
psychotropic medication in the neuropsychiatric group
seems, in our opinion, counterintuitive. However, the
frequency of psychiatric symptoms according to the
SCL-90-R in our cohort was 35.7% in the motor mani-
fest group and 19.6% in the premanifest group, which is
in accordance with the Van Duijn et al’s study [6].
It is important to recognise that both psychiatric symp-
toms and/or cognitive dysfunction may be stress disor-
ders, reactive to life events, and in the case of HD,
a transient reaction to receiving the genetic test result
[38], and therefore not necessarily a consequence ofneurodegeneration. However, the majority of our pre-
manifest participants completed the genetic counseling
procedure more than one year prior to inclusion in this
study, which makes a test-related reactive disorder less
likely. The criteria for cognitive impairment in our study
are consistent with severe impairment, and the cognitive
deficits in depression in general are described as mild to
moderate in group comparisons [39], a pattern which was
equally found in prodromal HD in the PREDICT-HD
study [40]. Therefore, cognitive impairment may not
solely be attributed to depression or other psychiatric
symptoms but a consequence of the neuropathological
changes as well.
Antidepressants exert more positive than negative ef-
fects on cognitive dysfunction in patients with depression
[41]. The effect of antidepressants on cognitive perform-
ance has not been studied in HD; however, it seems likely
that treatment may also improve cognitive function due to
depression in HD gene-expansion carriers.
When applying our predefined criteria of cognitive im-
pairment and neuropsychiatric symptoms to a Danish
control cohort of 40 healthy HD gene-expansion negative
individuals, the frequency of cognitive impairment was, as
expected, 5%. The frequency of psychiatric symptoms was,
however, lower than the expected 10% [26], confirming
that our criteria for cognitive impairment and neuro-
psychiatric symptoms are suitable and adequately conser-
vative for use in the Danish population.
The patients included in this study all had an MMSE
score ≥24, a MoCA score ≥19 and a UHDRS motor ≤55.
These cut-off scores for inclusion were applied because
patients with lower scores would not be capable of doing
a meaningful neuropsychological testing in this study.
This selection has important implications because the
frequency of cognitive deficits and neuropsychiatric
symptoms in this selected group of HD gene-expansion
carriers cannot be generalised to the entire HD popula-
tion. A small subgroup of invited participants either de-
clined participation or did not meet for arranged trial
dates. Evaluating the patient files of this patient group
showed that the majority of these patients would have
been classified in the neuropsychiatric group. We there-
fore hypothesise that both cognitive impairments and
psychiatric symptoms are more frequent in the “general”
HD population.
Despite these limitations, we demonstrate the import-
ance of the assessment of all HD gene-expansion carriers
with motor, neuropsychiatric, and cognitive measures
regularly to ensure sufficient and early treatment and so-
cial intervention.
Conclusion
Almost 40% of the gene-expansion carriers without
motor symptoms had either neuropsychiatric symptoms,
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patients are not premanifest in psychiatric and cognitive
terms. Currently, the clinical diagnosis of HD relies on
motor symptoms; however, both cognitive impairment
and neuropsychiatric symptoms may be very early and
substantial signs, and as it is impossible to predict the
symptom complex of premanifest gene-expansion carriers,
we recommend that all HD gene-expansion carriers are
referred to/offered a regular follow-up programme that in-
cludes a baseline neuropsychological and neuropsychiatric
evaluation as early as possible. This is further underlined
by the fact that the large negative impact that psychiatric
illness has on the quality of life and the major burden that
it places on relatives [42] can be alleviated or potentially
eliminated. Therefore, screening for psychiatric symptoms
in HD has important perspectives. Furthermore, to ac-
knowledge the high proportion of gene-expansion carriers
who, based on the lack of motor symptoms, traditionally
are classified as “premanifest”, but who have psychiatric
symptoms, cognitive deficits, or both, we propose a new
clinical classification into three different groups: premani-
fest, without symptoms or signs within the triad spectrum;
non-motor-manifest, with neuropsychiatric and/or cogni-
tive impairment, but without motor signs; and motor-
manifest, with motor signs, and possible neuropsychiatric
and/or cognitive impairment. Our predefined criteria for
neuropsychiatric and cognitive impairment, however, will
have to be elaborated and validated further in larger
cohorts.
It is important to recognise that both psychiatric and/
or cognitive symptoms may be stress-related disorders
and therefore e.g. a depression may stand alone as a
diagnosis in premanifest HD subjects, without fulfilling
the criteria for non-motor manifest.
The suggested classification will make a diagnosis of
manifest HD possible on neuropsychiatric and/or cogni-
tive impairment alone, and thereby ensure early and
relevant treatment and psycho-social intervention for
the benefit of the patients, relatives, and caregivers.
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